Rapid effectiveness of certolizumab pegol in non-radiographic axial spondyloarthritis

Reumatismo

G. Valesini¹  A. Scarno¹  A. Spadaro¹  A. Carboni¹  F.M. Perrotta¹  C. Catalano²  E. Lubrano³ 

[1] Dipartimento di Medicina Interna e Specialità Mediche, U.O.C. di Reumatologia, Università “La Sapienza”, Roma;Dipartimento di Medicina Molecolare, Radiologia Centrale U.O.C. A, Università “La Sapienza”, Roma;Dipartimento di Medicina e di Scienze per la Salute, Università del Molise, Campobasso;

关键词: Certolizumab pegol, Axial spondyloarthritis, Magnetic resonance.;   

DOI  :  10.4081/reumatismo.2013.134

来源: DOAJ

【 摘 要 】

In axial spondyloarthritis (SpA), the efficacy of certolizumab pegol (CZP), a novel pegylated anti-tumor necrosis factor alpha drug has not been investigated. We report that CZP showed a rapid effectiveness, assessed clinically and by magnetic resonance imaging, in a patient with a non-radiographic axial SpA, classified according to Assessment in SpondyloArthritis International Society (ASAS) criteria. This case suggests that CZP could be considered an useful treatment in non-radiographic axial SpA, supporting that an earlier therapeutic approach could play a relevant role in the management of the disease.

【 授权许可】

Unknown